Which is why I've been saying RAC's MC is very overvalue right now for a single IP which hasn't even started Ph1 clinical trial for RC220. Again, IMU has 5 IP and VAXINIA has already seen efficacy in Ph1 clinical trial which is usually seen toward the end of Ph2 clinical trial, Azer-Cel is actually close to Ph2/3 clinical trial and both CF33 and Azer-Cel has the possibility of expansion into other solid and liquid cancer market so MC of around $7-800M will be a reasonable value right now.
IMU Price at posting:
4.1¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)